Zeiher Study Likely Predicts The Outcome Of NeoStem's AMR-001 Trial
5d 1m 3m 1y 5y 10y
There are 3 articles on this stock available only to PRO subscribers.
There are no Transcripts on NBS.
GlobeNewswire (Mon, 7:30AM)
GlobeNewswire (Feb 27, 2014)
NeoStem CEO Dr. Robin Smith Interviewed on Clear Channel's "The Traders Network" Business Talk RadioMarketwire (Feb 19, 2014)
GlobeNewswire (Feb 4, 2014)
GlobeNewswire (Feb 3, 2014)
GlobeNewswire (Jan 28, 2014)
GlobeNewswire (Jan 6, 2014)
GlobeNewswire (Jan 2, 2014)
at MarketWatch.com (Jul 13, 2011)
at MarketWatch.com (Nov 16, 2010)
NBS vs. ETF Alternatives
Tuesday, Feb 42:01 PM|Tuesday, Feb 42:01 PM| Comment!
Monday, Jan 68:50 AM
Monday, Jan 68:50 AM| 1 Comment
- Neostem (NBS) has received a notice of allowance for what is the sixth granted or allowed U.S. patent for the company's AMR-001 drug, which is designed to preserve heart function after a severe heart attack.
- In addition, the EU intends to grant two patents for AMR-001; these would be Neostem's first patents in the region.
- AMR-001's total worldwide IP coverage is now 16 granted and allowed patents. (PR)
Thursday, Jan 212:45 PM
Thursday, Jan 212:45 PM| 5 Comments
- Moving sharply higher on the day are shares of NeoStem (NBS +11.7%).
- Helping the cause is Aegis' Ram Selvaraju who is "enthused about the completion of enrollment [in PreSERVE], given the lengthy period of time that this trial has taken to accrue the requisite number of patients."
- The analyst remains "confident that the AMR-001 Phase 2 study has a high likelihood of success."
- Price target hiked to $23 (from $21). For what it's worth, that represents upside of 240% from Tuesday's close.
Friday, Oct 42013, 12:48 PM|Friday, Oct 42013, 12:48 PM| 1 Comment
Friday, Oct 42013, 9:12 AM
Friday, Oct 42013, 7:47 AM|Friday, Oct 42013, 7:47 AM| 2 Comments
Tuesday, Sep 172013, 9:59 AM
Tuesday, Sep 172013, 9:59 AM| 2 Comments
- NeoStem (NBS +2.2%) say that the Data Safety Monitoring Board for the Phase II trial of its AMR-001 drug has recommended continuing the study following a third interim data and safety review.
- AMR-001 is being tested for its ability to preserve heart function after a severe heart attack, with the trial comprising 160 patients. (PR)
Monday, Sep 162013, 2:13 PM
Monday, Sep 162013, 2:13 PM| 4 Comments
- NeoStem (NBS -11.1%) started the day in positive territory but quickly faded into the red and is now down double-digits.
- It looks likely that an article by SA contributor Probio Invest is weighing on the shares.
- Probio says a study that showed autologous stem cells did not boost heart function "clearly does not bode well for NBS' AMR-001."
Monday, Sep 162013, 12:46 PM|Monday, Sep 162013, 12:46 PM| Comment!
Monday, Sep 162013, 8:12 AM
Monday, Sep 162013, 8:12 AM| Comment!
- NeoStem (NBS) obtains worldwide licensing rights to three families of patents from the University of California, San Francisco, providing the company with "incremental protection" for its human Regulatory T cell ("Treg") platform.
- The IP cover Treg's potential for treating autoimmune disorders, including Type 1 diabetes.
- NeoStem's IP for Treg includes the rights to use 22 patents in the U.S. and other major regions. (PR)
Thursday, Sep 122013, 3:32 PM
Thursday, Sep 122013, 3:32 PM| 2 Comments
- On Wednesday, a study published in the journal Nature, showed scientists were able to reprogram mature cells in mice, effectively "turning back the hands of time" (to use Bloomberg's expression), and forcing the cells to revert to a form of stem cell which can differentiate into other kinds of cells.
- Incredibly, the reprogrammed induced pluripotent stem cells ((iPS)) showed more potential — in terms of their ability to change into different cell types — than either embryonic stem cells or normal iPS cells.
- The idea is that scientists may one day be able to regenerate damaged tissue inside a patient's body. Previously, researchers had only demonstrated the ability to forcibly reprogram the cells in petri dishes. (more here)
- GERN CUR STEM PSTI NBS
Thursday, Sep 122013, 2:28 PM
Thursday, Sep 122013, 2:28 PM| 1 Comment
- NeoStem (NBS +6.4%) jumps after saying the National Institute of Arthritis and Musculoskeletal and Skin Diseases has awarded the company nearly $148K for the "Development of Adult Pluripotent VSEL stem cells to treat skin wounds in Scleroderma."
- Depending on the results of the study (which will employ a tight skin mouse), the company may be eligible to receive an additional $1.5M in grants. (PR)
Monday, Aug 192013, 4:27 PM
Monday, Aug 192013, 4:27 PM| Comment!
- NeoStem (NBS +4.9%) finishes solidly higher today after announcing that it's appointed Robert Dickey IV as its Chief Financial Officer.
- Dickey has over 15 years of management experience at life sciences companies, and replaces current CFO Larry May, who is assuming the newly-created position of VP, Strategic Initiatives.
Monday, Aug 122013, 8:18 AM
Monday, Aug 122013, 8:18 AM| Comment!
- NeoStem (NBS) unit Progenitor Cell Therapy adds a couple of execs, appointing Robert Shaw as VP of Commercial Sales and Brian Hampson as Senior Director of a new department called Engineering & Innovation.
- Shaw has held several positions at EMD Millipore, a supplier to the life science industry, while Hampson worked at Michigan-based Aastrom Biosciences for the last two decades. (PR)
Thursday, Aug 82013, 5:25 PM
Tuesday, Aug 62013, 3:04 PM
Tuesday, Aug 62013, 3:04 PM| Comment!
- NeoStem (NBS +6.7%) trades up again today after the cellular therapy company switched to the NASDAQ Stock Market from the NYSE yesterday.
- Additionally, it's also named Dr. Douglas W. Losordo as its chief medical officer.
- Dr. Losordo most recently was vice president of New Therapies Development, Regenerative Medicine and Baxter Ventures at Baxter International.